The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

Calcified Tissue International

Volumn 71, Issue 2, 2002, Pages 103-111

  Brown, J P ^a   Kendler, D L ^b   McClung, M R ^c   Emkey, R D ^d   Adachi, J D ^e   Bolognese, M A ^f   Li, Z ^g   Balske, A ^g   Lindsay, R ^h  

^a LAVAL UNIVERSITY   (Canada)

^b Providence Health Care   (Canada)

^c Osteoporosis Research Center   (United States)

^d READING HOSPITAL AND MEDICAL CENTER   (United States)

^e ST JOSEPH S HOSPITAL   (Canada)

^f Bethesda Health Research   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h HELEN HAYES HOSPITAL   (United States)

Author keywords

Bone mineral density; Fractures; Postmenopausal osteoporosis; Risedronate

Indexed keywords

CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCORING SYSTEM; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMUR NECK; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PATHOLOGY; SPINE FRACTURE; STOMACH; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; STOMACH; TREATMENT OUTCOME;

EID: 0036690206     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-002-2011-8     Document Type: Article

References (22)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285:785-795
2. Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992). Perspective. How many women have Osteoporosis? J Bone Miner Res 7(9):1005-1010
3. Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151:2026-2032
4. Ross PD (1997) Clinical consequences of vertebral fractures. Am J Med 103(2A):30S-43S
5. Ettinger B, Black DM, Nevitt MC, Rundle AC, Cauley JA, Cummings SR, Genant HK, and The Study of Osteoporotic Fractures Research Group (1992) Contribution of vertebral deformities to chronic back pain and disability. J Bone Miner Res 7:449-456
6. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata AL, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323
7. Melton LJ 3rd, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214-221
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal Osteoporosis. A randomized controlled trial. JAMA 282:1344-1352
9. Reginster J, Minnie HW, Sorenson OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, (2002) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
10. McClung MR, Geusens P., Miller PD, Zippel H, Gensen WG, Roux C, Adami S, Fogelman I, Daimond T, Eastell R, Meunier PJ, Reginster J-Y, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, for the Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
11. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ, for the Alendronate Once Weekly Study Group (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1-12
12. Mitchell DY, Eusebio RA, Sacco-Gibson NA, Pallone KA, Kelly SC, Nesbitt JD, Brezovic CP, Thompson GA, Powell JH (2000) Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 40:258-265
13. Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Lindsay RL (1995) Prevalence of low femoral bone density in older US women from NHANES III. J Bone Miner Res 10:796-802
14. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semi-quantitative technique, J Bone Miner Res 8:1137-1148
15. International Committee on Harmonization. Statistical Principals for Clinical Trials. Adopted by the CPMP, March 1998
16. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster J-Y (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind placebo-controlled trial. J Clin Endrocrinol Metab 85:1895-1900
17. Kanis JA (1996) Textbook of Osteoporosis. Blackwell Science Ltd., Oxford pp. 308-367
18. Singer FR, Clemens TL, Eusebio RA, Bekker PJ (1998) Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83:1906-1910
19. Hosking DJ, Eusebio RA, Chines AA (1998). Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 22:51-55
20. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ, for the Paget's Risedronate/Etidronate Study Group (1999). A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 106:513-520
21. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ (1998) Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032-1038
22. Brown JP, Hosking DJ, Ste-Marie LG, Johnston CC, Reginster J-Y, Ryan WG, Johnson TD, Bekker PJ (1999) Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. Calcif Tissue Int 64:93-99